HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG
TAE LIFE SCIENCES
Investors & News
2020 | Market Watch
TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.
2019 | Cision PR Newswire
TAE Life Sciences Announces Scientific Advisory Board to Advance Cancer Research in Boron-Neutron Capture Therapy
BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.
2019 | PR Newswire
TAE Life Sciences Adds Seasoned Chief Operating Officer to Scale New Radiation Treatment Platform
Robert Hill brings expertise in the technical and clinical development of radiation systems to speed platform research and commercialization.